Prestigious international recognition for Andrea Pretta , doctor-surgeon specialized at the School of Medical Oncology of the University of Cagliari .
For him one of the most important “Merit Awards” for the work presented at the “2022 ASCO Congress”, the most important international congress in the sector, organized by the American Society of Oncology . The works will take place in Chicago starting June 3.
The abstract signed by Dr. Pretta, entitled "Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy", provided for the evaluation of the relationship between lymphocytes and circulating monocytes , measured before starting the course of care in patients with stage IV pancreatic adenocarcinoma, as a factor related to response to treatment and overall survival.
Patients with a value ≥ 4 would have a better response to treatment and greater overall survival than patients with a value <4. Therefore, in the first group of patients, greater activity of lymphocytes and the immune system can be hypothesized, which could allow a better selection of patients eligible for immunotherapy.
WHO IS - Andrea Pretta is a surgeon specializing in medical oncology at the School of Specialization in Medical Oncology of the University of Cagliari. He is currently a PhD student in Molecular and Translational Medicine at the Sardinian University (with Prof. Mario Scartozzi as tutor) and since January 2022 he has been active in the Clinical Trials Group, Medical Oncology, University of Cagliari.
Since the beginning of the specialist training course, the researcher has developed a particular clinical-scientific interest in tumors of the gastro-enteric tract.
(Unioneonline / vl)
